ArticleBio-protocol2021
Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes.
Article in Bio-protocol, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 57 citations in OpenAlex.
- Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers.Scientific reports · 2023Trial
- Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.PloS one · 2022Trial
- Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.Emerging microbes & infections · 2025Article
- Compartmentalised mucosal and blood immunity to SARS-CoV-2 is associated with high seroprevalence before the Delta wave in Africa.Communications medicine · 2025Article
- A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses.Nature biomedical engineering · 2025Article
- Differential modulation of SARS-CoV-2 infection by complement factor H and properdin.Frontiers in immunology · 2025Article
- Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.British journal of haematology · 2024Article
- Cellular sialoglycans are differentially required for endosomal and cell-surface entry of SARS-CoV-2 in lung cell lines.PLoS pathogens · 2024Article
- Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.NPJ vaccines · 2024Article
- Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.Journal of translational medicine · 2024Article
- Conference Report: LPMHealthcare Emerging Viruses 2023 (EVOX23): Pandemics-Learning from the Past and Present to Prepare for the Future.Pathogens (Basel, Switzerland) · 2024Article
- A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.Cell reports. Medicine · 2024Article
- The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.Nature communications · 2024Article
- Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents.Scientific reports · 2024Article
- Antiviral Effects of Secondary Metabolites fromPlants (Basel, Switzerland) · 2023Article
- Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation.iScience · 2023Article
- Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera.Scientific reports · 2023Article
- Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein.Viruses · 2023Article
- Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.The journal of allergy and clinical immunology. Global · 2023Article
- Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
This protocol details a rapid and reliable method for the production and titration of high-titre viral pseudotype particles with the SARS-CoV-2 spike protein (and D614G or other variants of concern, VOC) on a lentiviral vector core, and use for neutralisation assays in target cells expressing angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). It additionally provides detailed instructions on substituting in new spike variants via gene cloning, lyophilisation and storage/shipping considerations for wide deployment potential. Results obtained with this protocol show that SARS-CoV-2 pseudotypes can be produced at equivalent titres to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) pseudotypes, neutralised by human convalescent plasma and monoclonal antibodies, and stored at a range of laboratory temperatures and lyophilised for distribution and subsequent application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.